ArticleScience advances2023
Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae.
Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- HURDLER: a cloning method to overcome length limits in designed repeat proteins.Nucleic acids research · 2026Article
- TheInternational journal of molecular sciences · 2026Article
- Coal Dust-Mimetic Carbon Nanoparticles Induce Colonic Epithelial Cell Senescence via p16/p21 Dual Pathways and Promote Colonic Inflammatory Response.Journal of gastroenterology and hepatology · 2026Article
- Computational design of a soluble mimic of the outer membrane LPS transport protein LptD suitable for screening of antibiotics.Protein science : a publication of the Protein Society · 2026Article
- Role of Disulfide Bond in Modulating the Antibacterial Activity and Structure of Cathelicidin-DM Peptides.Probiotics and antimicrobial proteins · 2026Article
- Targeting of the Gram-Negative Outer Membrane for Antibiotic Discovery and Potentiation.ACS infectious diseases · 2026Review
- Bacterial cell envelope-targeting antibiotics.Nature reviews. Microbiology · 2026Review
- Time-resolved transcriptomic analysis reveals envelope stress-mediated adaptation ofFrontiers in microbiology · 2026Article
- Structural snapshots of Pseudomonas aeruginosa LptBNature communications · 2025Article
- Conformational Plasticity of LptC Regulates Lipopolysaccharide Transport by the LptBJournal of the American Chemical Society · 2025Article
- Structures, Interactions, and Antimicrobial Activity of the Shortest Thanatin Peptide fromInternational journal of molecular sciences · 2025Article
- Global health perspectives on antibacterial drug discovery and the preclinical pipeline.Nature reviews. Microbiology · 2025Review
- Inhibiting Lipopolysaccharide Biogenesis: The More You Know the Further You Go.Annual review of biochemistry · 2025Review
- Novel bifunctional antibacterial peptides mediated by a covalent conjugation strategy combat priority multidrug-resistant gram-negative pathogens through dual targets.The Journal of antibiotics · 2025Article
- Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research.Angewandte Chemie (International ed. in English) · 2025Review
- Lipid Trafficking in Diverse Bacteria.Accounts of chemical research · 2025Review
- Review
- β-Hairpin Peptidomimetics for Protein-Protein Interaction Inhibition.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Single Disulfide Bond in Host Defense Thanatin Analog Peptides: Antimicrobial Activity, Atomic-Resolution Structures and Target Interactions.International journal of molecular sciences · 2024Article
- Discovery of Novel Thanatin-like Antimicrobial Peptides from Bean BugPharmaceutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
The rise of antimicrobial resistance poses a substantial threat to our health system, and, hence, development of drugs against novel targets is urgently needed. The natural peptide thanatin kills Gram-negative bacteria by targeting proteins of the lipopolysaccharide transport (Lpt) machinery. Using the thanatin scaffold together with phenotypic medicinal chemistry, structural data, and a target-focused approach, we developed antimicrobial peptides with drug-like properties. They exhibit potent activity against Enterobacteriaceae both in vitro and in vivo while eliciting low frequencies of resistance. We show that the peptides bind LptA of both wild-type and thanatin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.